TickerFacts.

Company research / PRLD

Prelude Therapeutics Inc (PRLD)

Build a valuation ↗↓ Download CSV

CIK 0001678660 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Prelude Therapeutics Inc reported revenue of $12.14M. Revenue grew 73.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $22.42M.

Key ratios (year ended 2025-12-31)

-861.3%
Operating margin
-819.6%
Net margin
-145.0%
Return on year-end equity
73.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-10

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$22.42M$12.14M$7.00Mn/an/an/an/an/a
R&D Expense$69.43M$94.30M$118.00M$103.39M$92.89M$86.78M$48.18M$24.28M
Operating Income-$67.40M-$104.57M-$139.71M-$132.28M-$123.54M-$113.73M-$58.76M-$28.11M
Depreciation & Amortization$1.59M$1.71M$1.77M$1.17M$1.32M$915.0K$542.0K$382.0K
EBITDA-$65.81M-$102.86M-$137.94M-$131.11M-$122.22M-$112.82M-$58.22M-$27.73M
Net Income-$60.49M-$99.50M-$127.17M-$121.83M-$115.44M-$111.69M-$56.93M-$27.57M
EPS (Diluted)n/a-$1.29-$1.68-$2.02-$2.44-$2.43n/an/a
Total Assets$189.36M$141.31M$175.51M$277.67M$220.50M$305.10M$223.59M$21.87M
Total Liabilities$55.63M$72.68M$44.06M$40.58M$25.06M$19.20M$11.41M$4.84M
Shareholders' Equity$133.73M$68.64M$131.46M$237.09M$195.44M$285.90M$212.18M-$49.41M
Cash & Equivalents$26.33M$35.26M$12.47M$25.29M$30.61M$31.83M$218.31M$18.88M
Operating Cash Flow-$33.26M-$56.30M-$102.89M-$107.06M-$83.73M-$83.53M-$46.18M-$25.66M
Capital Expenditures$0$67.0K$764.0K$3.51M$3.02M$2.32M$621.0K$780.0K
Free Cash Flow-$33.26M-$56.37M-$103.65M-$110.58M-$86.75M-$85.85M-$46.80M-$26.45M
Weighted Average Diluted Sharesn/a76.96M75.81M60.36M47.37M46.05Mn/an/a
EPS (Basic)n/a-$1.29-$1.68-$2.02-$2.44-$2.43n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView